Exclusive Webinar :Gain complete knowledge about how you can invest in global markets during an insightful webinar on April 16 at 11 am. Register Now!
you are here: HomeNewscoronavirus

COVID-19 Update | Coronavirus variants from Brazil, South Africa are less susceptible to antibodies, says study

The study noted that vaccination or recovery from COVID-19 may offer reduced protection from SARS-CoV-2 variants B.1.351 and P.1.

March 28, 2021 / 05:56 PM IST
Source: Reuters

Source: Reuters

Variant forms of the novel coronavirus which were first reported in South Africa and Brazil are less efficiently inhibited by antibodies from recovered patients and vaccinated individuals, a new study confirms. According to the research, published in the journal Cell, recovery from COVID-19 as well as vaccination may offer only incomplete protection against these mutant virus forms.

"This is worrisome because the rapid spread of variants that might not be efficiently inhibited by antibodies could undermine our current vaccination strategy," said Stefan Pohlmann, a co-author of the study from the German Primate Center in Gottingen. These virus variants have mutations in the spike protein — the structure on the surface of the virus that is responsible for attachment to host cells — the researchers said.

COVID-19 Update | South Africa plans to vaccinate 200,000 people daily against coronavirus: Report

In order for the virus to enter a cell, they said it must first attach to the host cell surface using its spike protein, which is located on the viral envelope. The spike protein is also the target for antibody therapies and vaccines aimed at preventing the virus from replicating in the body, they researchers added.

Based on the research, the scientists said an antibody used for COVID-19 therapy did not inhibit the South African and Brazilian coronavirus variants — B.1.351 and P.1. "Moreover, these variants were less well inhibited by antibodies from convalescent or vaccinated individuals, they partially bypassed the neutralising effect of the antibodies," said Jan Munch, another co-author of the study.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
The study noted that vaccination or recovery from COVID-19 may offer reduced protection from SARS-CoV-2 variants B.1.351 and P.1. "Our findings show that it is important to limit the spread of the virus as much as possible until widespread vaccination is feasible. Otherwise, we risk the emergence of new variants that cannot be effectively controlled by the currently available vaccines," said Markus Hoffmann, first author of the study.
PTI
first published: Mar 28, 2021 05:56 pm

stay updated

Get Daily News on your Browser
Sections